[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"als---amyotrophic-lateral-sclerosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:als---amyotrophic-lateral-sclerosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,70,118,140,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":13,"conditions":23,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100634721","independence-through-endovascular-neuroprosthetic-technology-intent-an-early-feasibility-study-100634721",false,"NCT07543367","INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study","Inclusion Criteria:\n\n* Able to provide informed consent to participate in the study.\n* Diagnosis of ALS, with bilateral upper-limb paresis.\n* ALS must be refractory to treatment and have been present for a minimum of six months.\n* Aged 22 years or older.\n* Life expectancy greater than 12 months post-implantation.\n* Preserved precentral gyrus assessed using CT.\n* Suitable vascular anatomy assessed using CT venography.\n* Suitable anatomy for subcutaneous pocket creation.\n* Able to undergo anesthesia.\n* Willing and able to comply with all investigational requirements, including clinical testing visits and training visits in the home.\n* Caregiver(s) willing and able to facilitate study visits, including visits to the study site and in the home, and BCI use outside of study visits (e.g., device charging).\n* Patient and caregiver fluent in English.\n* Suitable home environment for BCI training.\n\nExclusion Criteria:\n\n* Active infection or unexplained fever in the 48 hours prior to informed consent.\n* Major psychiatric disorder that may adversely impact the participant's safety or study compliance, including severe depression, psychotic features, personality disorder, severe emotional lability, or substance abuse.\n* Diagnosis of ALS-FTD or another dementia.\n* Active implanted device (e.g., deep brain stimulator, cardiac defibrillator, pacemaker, vagal nerve stimulator, spinal cord stimulator, diaphragmatic pacer, etc.).\n* Known allergy to patient-contacting materials included in the implanted device.\n* Contraindication to angiographic imaging or iodine contrast media.\n* History of central venous sinus thrombosis.\n* Recent history of new venous thromboembolic event (in the 6 months prior to implant), recurrent history of venous thromboembolic disease, or hypercoagulable state.\n* Contraindication to antithrombotic therapy.\n* Participant is at substantially increased risk of infection, including immunocompromised status, recurrent or chronic infection, or poorly controlled diabetes mellitus.\n* Significant risk of non-healing of the subcutaneous pocket incision, including history of chronic non-healing surgical wounds or poorly controlled diabetes mellitus.\n* Pregnant or breast feeding.\n* Patients who are currently enrolled in any other clinical trial that would confound interpretation of safety or effectiveness data or may interfere with the ability to meet study requirements.\n* Any other disease or disorder that could significantly affect participation in the study. Examples may include corrected vision insufficient for viewing computer screens or hearing insufficient for following verbal instructions, which might impact the participant's ability to participate in BCI training and testing.","ALL","22 Years",{"count":18,"type":19},10,"ESTIMATED","INTERVENTIONAL",[22],"NA",[24,25,26,27,28],"Neurological Disorder","ALS (Amyotrophic Lateral Sclerosis)","Motor Neuron Disease","ALS - Amyotrophic Lateral Sclerosis","ALS","RECRUITING","2026-05-07",{"date":32,"type":33},"2026-05-11","ACTUAL",{"date":35,"type":19},"2026-04",{"date":37,"type":19},"2029-12",{"name":39,"class":40},"Synchron, Inc.","INDUSTRY",5,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":20,"phases":53,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100615698","tongue-strengthening-exercises-in-people-with-als-100615698","NCT07295990","Tongue-strengthening Exercises in People With ALS.","The Impact of Dysphagia Exercise on Oropharyngeal Swallowing Function in Patients With ALS","Inclusion Criteria:\n\n* Diagnosis of possible, probable, or definite ALS (El-Escorial Revisited)\n* Lingual exercises naïve\n* Impaired lingual strength generation compared to normative data\n* EAT-10 score \\\u003C3\n\nExclusion Criteria:\n\n* Stroke\n* Head injury\n* Head and neck cancer\n* Tracheostomy\n* Other concomitant neurogenic disorder\n* Recent oral surgery other than routine dental surgery\n* Unable to generate isometric lingual pressure on lingual manometer\n* Participation in another clinical trial intervention that may confound results\n* NPO (nothing by mouth)\n* Anarthric","18 Years","99 Years",{"count":52,"type":19},20,[22],"This study is testing a tongue exercise program for people living with ALS to see if it can help support speech and swallowing. All participants will receive the treatment, and researchers will measure changes over time by comparing each person's results to their own earlier results.\n\nPeople who join the study will have two in-person visits and four weekly telehealth sessions with a speech-language pathologist. During these sessions, participants will practice tongue resistance exercises, complete speech and swallowing tasks, and answer surveys about their experience. They will also use a small device at home to measure tongue strength and swallowing.\n\nThe exercise program involves pressing the tongue against a device several times a day, five days per week, for five weeks. Researchers want to learn if this program is safe, practical, and helpful for people with ALS.",[25,27],[28,57,58,59],"Amyotrophic Lateral Sclerosis","Dysphagia","Dysarthria","2026-05-05",{"date":32,"type":33},{"date":63,"type":19},"2026-05-01",{"date":65,"type":19},"2029-01",{"name":67,"class":68},"Nova Southeastern University","OTHER",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":77,"sex":15,"minAge":49,"maxAge":78,"enrollmentInfo":79,"targetDuration":4,"studyType":20,"phases":81,"briefSummary":82,"conditions":83,"keywords":93,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":69},"100632087","ultra-high-resolution-pet-in-aging-neurodegeneration-and-psychotic-disorders-100632087","NCT07509125","Ultra-High Resolution PET in Aging, Neurodegeneration and Psychotic Disorders","Ultra-High Resolution PET of the Human Brain and Spinal Cord in Healthy Aging, Dementia, Movement Disorders, ALS and Psychotic Disorders","Inclusion Criteria:\n\n* WP1: Healthy controls\n* Age between 18 and 90 years old (15 aged 18-50 years and 25 aged 50 90 years);\n* Subject is judged to be in good health by the investigator on the basis of medical history, physical examination including vital signs and clinical laboratory tests;\n* No history or evidence of current major neurological, internal or psychiatric disorder, based on the medical assessment as described hereabove and neuropsychological assessment;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;\n* In subjects \\\u003C 60 years of age, a normal structural MRI scan as assessed by expert radiologist.\n* In subjects \\>= 60 years of age white matter hyperintensities corresponding to a WML (white matter lesion) score \\\u003C= 2 (of 3) on the Age-Related White Matter changes scale are acceptable;\n* When older than 50 years of age, the volunteer is willing to undergo a p- tau217 blood sample.\n* WP2: Dementia\n* Patient has a clinical diagnosis of biomarker-proven prodromal AD\n* WP3: ALS spectrum\n* Subject must meet El Escorial Criteria (30) and Awaji-Shima criteria (31) for at least possible ALS;\n* WP4: Movement disorders\n* (all): Patient (or legal representative, when applicable) is able to understand the patient information form and give written informed consent.\n* Parkinson´s disease (PD):\n* Patient has clinically established PD based on the Movement Disorder Society (MDS) diagnostic criteria (32);\n* Patient has an abnormal 18F-PE2I PET;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline.\n* Multiple system atrophy (MSA)\n* Patient has clinically established or clinically probable MSA-P based on the\n* Movement Disorder Society (MDS) diagnostic criteria (33);\n* Patient has an abnormal 18F-PE2I PET.\n* Progressive supranuclear palsy (PSP)\n* Patient has an abnormal 18F-PE2I PET;\n* Patient has clinically established probable PSP according to the latest MDS criteria\n* Dementia with Lewy bodies (DLB)\n* Patient has probable DLB by consensus criteria (cognitive impairment MoCA \\\u003C 26 + visual hallucinations and\u002For fluctuating alertness);\n* Patient has an abnormal 18F-PE2I PET.\n* Idiopathic REM sleep behavior disorder (iRBD)\n* Patient has Polysomnography-confirmed iRBD;\n* No evidence of cognitive impairment as assessed by a Montreal Cognitive Assessment (MoCA) score of 26 or higher at baseline;\n* No clinical evidence of parkinsonism at baseline.\n* WP5: Psychosis\n* DSM 5 criteria for a non-affective schizophrenia spectrum psychotic disorder;\n* Age between 18 and 55 years old for adult-onset psychosis, onset of psychosis (and age) above 60 years old for very late onset psychosis.\n\nExclusion Criteria:\n\n* Subject has a history of any major (other) internal, psychiatric or neurological disease that may interfere with the investigations (especially liver and kidney disease, uncontrolled diabetes, cancer, severe depression, stroke, severe TBI);\n* Subject is currently a user (including recreational use) of any illicit drugs, including cannabis, or has a history of drug or alcohol abuse;\n* Subject chronically uses medication that has central nervous system effects (e.g. strong painkillers such as opioids, neuroleptics,..; ) (other than prescribed for the illness in case of patients);\n* Subject has had exposure to ionizing radiation (\\> 1 mSv) in other research studies within the last 12 months;\n* Subject has a contra-indication for MRI scanning;\n* Subject suffers from claustrophobia or cannot tolerate confinement during PET-MRI scanning procedures; subject cannot lie still for (at least) 60 minutes inside the scanner;\n* (For subjects with arterial sampling): The subject is hypersensitive to lidocaine (used for local anaesthesia during the placement of the arterial catheter), has an abnormal Allen test (a test to check blood flow in the arteries of the forearm) or is on anti-coagulant therapy;\n* Subject (or his\u002Fher legal representative) does not understand the study procedures;\n* Subject is unwilling or unable to perform all of the study procedures, or is considered unsuitable in any way by the principal investigator;\n* Subject is potentially pregnant (hCG test can be done if doubt exists).",true,"90 Years",{"count":80,"type":19},300,[22],"The goal of this study is to use ultra-high-resolution (UHR) PET imaging to better understand how the brain and spinal cord change in healthy aging and in neurological and psychiatric disorders such as Alzheimer's disease (AD), Parkinson's disease and related movement disorders, amyotrophic lateral sclerosis (ALS), and psychotic disorders. Researchers will use the NeuroExplorer PET\u002FCT system, a new scanner that can show very small structures in the brain and spinal cord in much more detail than regular PET.\n\nThe main questions this study aims to answer are:\n\n* How do small but important brain regions (like the locus coeruleus, substantia nigra, and thalamic nuclei) change in healthy aging?\n* What early brain changes occur in neurodegenerative and psychotic disorders, and can they help improve early diagnosis?\n\nParticipants will:\n\n* Undergo PET and MRI brain scans using different tracers that measure brain metabolism (18F-FDG), synaptic density (¹⁸F-SynVesT-1), dopamine transporters (¹⁸F-PE2I), and tau protein buildup (¹⁸F-MK6240).\n* Complete cognitive and clinical assessments related to memory, mood, and motor or psychiatric symptoms, depending on their group.\n\nThis study will include healthy volunteers and patients with mild cognitive impairment due to Alzheimer´s disease, ALS, Parkinson's disease and related disorders, or psychotic disorders.\n\nThe results will help create detailed brain imaging maps for healthy aging and identify early biomarkers for different diseases to support better diagnosis and treatment in the future.",[84,27,85,86,87,88,89,90,91,92],"Alzheimer Dementia (AD)","Parkinson s Disease","REM Sleep Behavior Disorder (iRBD)","PSP - Progressive Supranuclear Palsy","MSA - Multiple System Atrophy","Dementia With Lewy Bodies (DLB)","ALS With Frontotemporal Dementia (ALS\u002FFTD)","Adult Onset Psychotic Disorder","Very Late Onset Psychotic Disorder",[94,95,96,57,97,98,99,100,101,102,103,104,105,106,107,108],"PET\u002FCT scan","Alzheimer´s disease","Dementia","Parkinson´s disease","REM sleep behavior disorders","Progressive supranuclear palsy","Multiple System Atrophy","Dementia with Lewy Bodies","Psychotic disorders","Schizophrenia","ALS with frontotemporal dementia","UHR PET","Locus coeruleus","Papez circuit","Thalamic subnuclei","2026-03-27",{"date":111,"type":33},"2026-04-03",{"date":113,"type":33},"2026-02-13",{"date":115,"type":19},"2029-09",{"name":117,"class":68},"Universitaire Ziekenhuizen KU Leuven",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":20,"phases":126,"briefSummary":127,"conditions":128,"keywords":129,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":69},"100630737","evaluation-of-a-structurally-suitable-neck-exoskeleton-in-patients-with-amyotrophic-lateral-sclerosis-100630737","NCT07491562","Evaluation of a Structurally Suitable Neck Exoskeleton in Patients With Amyotrophic Lateral Sclerosis","A Feasibility Trial to Evaluate Structural Suitability of a Robotic Neck Exoskeleton to Restore Head Movements in Patients With Amyotrophic Lateral Sclerosis","Inclusion Criteria:\n\n* ALS diagnosis and neck weakness\n\nExclusion Criteria:\n\n* Any cognitive deficits or visual impairments that would prevent from safely using the device and completing the tasks.",{"count":18,"type":19},[22],"The investigators will evaluate a new powered neck exoskeleton in patients with amyotrophic lateral sclerosis (ALS) to understand whether this device allows adequate head range of motion and achieves satisfaction from users. In this small cross-sectional device feasibility study, participants will be enrolled from the ALS clinic at the University of Utah Hospital. After obtaining written consent, participants will perform tasks using the neck exoskeleton. Tasks include computerized tracking tasks and simulated activities of daily living. Breaks will be added between tasks to avoid fatigue. Head-neck kinematics will be recorded, and range of motion will be computed. Participants will also report their satisfaction of the device.",[27],[130,28],"head drop","2026-03-19",{"date":133,"type":33},"2026-03-24",{"date":135,"type":33},"2024-09-06",{"date":137,"type":19},"2026-07-20",{"name":139,"class":68},"University of Utah",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":4,"enrollmentInfo":148,"targetDuration":150,"studyType":151,"phases":4,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":167,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":4},"100623727","healey-als-mymatch-common-screening-protocol-100623727","NCT07400393","Healey ALS MyMatch Common Screening Protocol","Healey ALS MyMatch Common Screening Protocol (MCSP) for Determining Preliminary Eligibility for ALS MyMatch Early Phase Clinical Trials","MCSP","Inclusion Criteria:\n\n1. Ability to provide written informed consent.\n2. Adults \\> 18 years of age.\n3. Diagnosis of symptomatic ALS that meets either the revised El Escorial Criteria.(clinically possible, probable, probable lab-supported, or definite) or the Gold Coast Criteria.\n4. Available or pending clinically obtained CLIA ALS genetic panel report.\n5. Time since onset of weakness due to ALS ≤ 24 months at the time of MCSP screening.\n6. Slow VC ≥ 65% of predicted capacity value for gender, height and age at screening.\n7. Clinically unremarkable Complete Blood Counts as per SI's discretion, including but not limited to Hemoglobin ≥ 9 g\u002FdL.\n8. Ability and willingness to complete all study procedures per SI's assessment.\n9. Negative pregnancy test at screening for women of child-bearing potential (WOCB), defined as a sexually mature woman who has not undergone a hysterectomy or who has not been naturally postmenopausal for at least 24 consecutive months (i.e., who has had menses any time in the preceding 24 consecutive months).\n\nExclusion Criteria:\n\n1. Clinically significant unstable medical or surgical condition that would pose a risk to the participant's trial procedural participation or interfere with data collection, per SI's assessment.\n2. Presence of cognitive or mental health disorders impairing ability to provide informed consent for the study per SI assessment.\n3. Active cancer or history of cancer, unless it was successfully treated for durable remission or cure more than 3 years ago. (Note that basal cell carcinoma, squamous cell carcinoma in situ, cervical carcinoma in situ, prostatic carcinoma in situ, or other malignancies that have been curatively excised at any time previously and with no evidence of disease recurrence for at least 3 years are not exclusionary.)\n4. Prior solid organ transplantation.\n5. Use of investigational treatments for ALS (off-label use or active participation in a clinical trial) within 5 half-lives (if known) or 30 days (whichever is longer) prior to the MCSP Screening Visit. (Please refer to the Manual of Procedures (MOP) for current list of experimental therapies)\n6. Screening 12-lead ECG showing QT interval corrected for rate (QTcF) \\> 470 msec for women and \\> 450 msec for men, absence of second degree or higher AV block or other clinically significant cardiac arrythmias.\n7. Clinically significant abnormalities in the Comprehensive Metabolic Panel per SI's assessment, including but not limited to:\n\n   1. Serum alanine aminotransferase or aspartate aminotransferase \\> 3 times the upper limit of normal, or serum bilirubin \\> 1.5 × upper limit of normal\n   2. Estimated GFR (eGFR) of \\\u003C 30 mL\u002Fmin\u002F1.73m2\n8. Other clinically significant electrolyte and metabolic abnormalities\n9. If female, breastfeeding, pregnant, or of child-bearing potential and unwilling to use effective contraception for duration of the trial and after discontinuing treatment as outlined in the ALS MyMatch trial protocol.\n10. Clinically significant unstable medical conditions (other than ALS) that would pose a risk to the participant, per SI's assessment (e.g., cardiovascular instability, systemic infection,), or clinically significant laboratory abnormality or ECG changes.\n11. Exposure at any time to any gene therapies under investigation for the treatment of ALS (off-label use or investigational).\n12. Participants who require Permanent assisted ventilation (PAV). PAV defined as more than 22 hours per day of noninvasive or invasive mechanical ventilation for more than seven consecutive days. The date of onset of PAV is the first day of the seven days.",{"count":149,"type":19},500,"45 Days","OBSERVATIONAL","The goal of the Healey ALS MyMatch Common Screening Protocol (MCSP), an observational study, is to identify individuals with ALS who may be eligible to be matched to a currently enrolling ALS MyMatch trial. Participants will complete a MCSP Screening Visit and undergo clinical assessments, laboratory testing, and biomarker analyses to determine preliminary trial eligibility. The study also characterizes clinical, genetic, and biofluid biomarker profiles, assesses the prevalence of ALS-associated gene variants, and banks blood samples for future ALS and biomarker research. MCSP enables simultaneous screening for multiple trial-specific biomarkers and uses a targeted medical history form to optimize matching of participants to appropriate MyMatch trials.",[28,25,27],[28,57,155,156,157,146,158,159,160,161,162,163,164,165,166],"MyMatch","ALS MyMatch","MyMatch Program","MyMatch Common Screening Protocol","Early Phase","Biomarker","Phase I","Phase II","Healey","NCRI","ALS Trials","MGB","NOT_YET_RECRUITING","2026-02-06",{"date":170,"type":33},"2026-02-10",{"date":172,"type":19},"2026-03-16",{"date":174,"type":19},"2029-03-16",{"name":176,"class":68},"Massachusetts General Hospital",{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":11,"sex":15,"minAge":49,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":20,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":69},"100566036","controlling-amyotrophic-lateral-sclerosis-motor-neuron-excitability-study-100566036","NCT06649955","Controlling Amyotrophic Lateral Sclerosis Motor Neuron Excitability Study","CALM","Inclusion Criteria:\n\n1. 18-80 years of age inclusive\n2. Sporadic or familial ALS diagnosed as clinically possible, probable, lab-supported probable, or definite ALS as defined by revised El Escorial criteria\n3. Less than or equal to 3 years since ALS symptom onset\n4. Slow Vital Capacity ≥ 50% of predicted capacity at the time of Screening as determined using a portable spirometer\n5. For TTNCS: Median CMAP ≥ 1.5 mV\n6. Willing to forgo botulinum toxin, phenol or alcohol injections, intrathecal baclofen, digitalis, and morphine for the study duration\n7. Willing to refrain from participation in any other therapeutic clinical trial or investigational product for ALS for the duration of this study\n8. Women must not be able to become pregnant (e.g., post-menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and 3 months after study completion.\n9. Stable dose of rilutek (Riluzole), edaravone (Radicava), or tofersen (Qualsody) and oral medications for muscle spasms\u002Fcramps (e.g. mexiletine, quinine, quinidine, magnesium, gabapentin, oxcarbazepine, baclofen) for at least 30 days prior to the onset of participation in the study\n10. ALS Functional Rating Score (ALSFRS-R) of greater than or equal to 35\n11. Willing and able to give informed consent\n\nExclusion Criteria:\n\n1. Study participants who are on permanent assisted ventilation (PAV) defined as \\>22h of noninvasive or invasive ventilation a day for \\> 7 consecutive days.\n2. Study participants who have been diagnosed with ALS having only clinical bulbar involvement\n3. Implanted intrathecal pump\n4. Prior botulinum toxin injection(s) at any site within 12 weeks of study enrollment\n5. Prior phenol or alcohol injections for spasticity within 6 months of study enrollment\n6. Presence of potential tsDCS and\u002For TMS risk factors:\n\n   1. Damaged skin at the stimulation sites (i.e., skin with ingrown hairs, acne, razor nicks, wounds that have not healed, recent scar tissue, broken skin, etc.)\n   2. Presence of an electrically, magnetically or mechanically activated implant (including cardiac pacemaker) or any other electrically sensitive support system with the exception of loop recorders\n   3. Ferromagnetic metal in the head, neck or any site of stimulation including, but not limited to, aneurysm clips, implanted medication pumps, implanted brain stimulators, pacemakers, cochlear implants, implanted metal prostheses or metal due to any injury; dental fillings are permitted. Jewelry must be removed during stimulation\n   4. Seizures or unexplained spells of loss of consciousness during the previous 12 months\n   5. Any cardiac abnormality that may be exacerbated by transthoracic electrical stimulation\n   6. History of cord lesions or previous spinal surgery that may interfere with procedure as determined by the study MD\n   7. History of intracranial brain lesions, cortical stroke or previous neurosurgery that may interfere with TMS (e.g., in regions to be stimulated for TMS evaluations) as reviewed and approved by the study MD\n7. Any medical condition that would prevent the participant from being able to participate in the clinical outcome measures\n8. Pregnant females, as determined by a pregnancy test at V1 (in females of child-bearing potential)","80 Years",{"count":186,"type":19},15,[22],"Following completion of the ALS Early Feasibility Study of the MyoRegulator® device for treatment of ALS (NCT06165172), the CALM study will further assess the feasibility of the MyoRegulator® device to treat ALS in an expanded number of individuals with ALS. CALM will gather additional preliminary evidence of clinical safety and potential effectiveness in this patient population with a longer follow-up period and additional secondary endpoints in a single-arm study prior to commencing a larger sham-controlled pivotal trial.",[27],[28,191,192,193],"Lou Gehrig's disease","Non-invasive","Multi-site direct current stimulation (multi-site DCS)","2026-01-16",{"date":196,"type":33},"2026-01-20",{"date":198,"type":33},"2025-02-10",{"date":200,"type":19},"2026-11",{"name":202,"class":40},"PathMaker Neurosystems Inc."]